What's new

Human medicines European public assessment report (EPAR): Enjaymo, sutimlimab, Date of authorisation: 15/11/2022, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Enjaymo, sutimlimab, Date of authorisation: 15/11/2022, Revision: 5, Status: Authorised

Mar 21, 2025 - 14:38
 0
Human medicines European public assessment report (EPAR): Enjaymo, sutimlimab, Date of authorisation: 15/11/2022, Revision: 5, Status: Authorised
Human medicines European public assessment report (EPAR): Enjaymo, sutimlimab, Date of authorisation: 15/11/2022, Revision: 5, Status: Authorised
Read More

Tags:

Previous Article

More Than 1,300 Flights Cancelled As Fire Shuts World's Second-Busiest Airport

Next Article

Food/agriculture industry seen as ‘backbone of US economy’

Related Posts

P/87/2010

P/87/2010

Feb 9, 2025  0

Human medicines European public assessment report (EPAR): Idefirix, imlifidase, Date of authorisation: 25/08/2020, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 20, 2025  0

Opinion/decision on a Paediatric investigation plan (PIP): RoActemra, tocilizumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Infections and infestations, PIP number: P/0028/2024

Opinion/decision on a Paediatric investigation plan (PI...

Mar 12, 2025  0